Fax: (416) 864-5648
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the Breast Cancer Family Registry
Article first published online: 2 NOV 2010
DOI: 10.1002/cncr.25642
Copyright © 2010 American Cancer Society
Additional Information
How to Cite
Mulligan, A. M., Pinnaduwage, D., Bane, A. L., Bull, S. B., O'Malley, F. P. and Andrulis, I. L. (2011), CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the Breast Cancer Family Registry. Cancer, 117: 1350–1359. doi: 10.1002/cncr.25642
Publication History
- Issue published online: 18 MAR 2011
- Article first published online: 2 NOV 2010
- Manuscript Accepted: 9 AUG 2009
- Manuscript Revised: 6 JUL 2009
- Manuscript Received: 8 MAR 2009
REFERENCES
- 1, , , et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266: 66-71.
- 2, , , et al. Novel consensus DNA-binding sequence for BRCA1 protein complexes. Mol Carcinog. 2003; 38: 85-96.Direct Link:
- 3. BRCA1 in cancer, cell cycle and genomic stability. Front Biosci. 2003; 8: s1107-1117.
- 4. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002; 108: 171-182.
- 5, . Breast and ovarian cancer. N Engl J Med. 2003; 348: 2339-2347.
- 6, , , et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415: 530-536.
- 7, , , et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100: 8418-8423.
- 8, , , et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002; 20: 2310-2318.
- 9, , , et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998; 90: 1138-1145.
- 10, , , et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005; 11: 5175-5180.
- 11Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med. 2005; 143: 355-361.
- 12, , , et al. Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. Ann Oncol. 1998; 9: 939-950.
- 13, , , et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007; 107: 159-162.
- 14, , , et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst. 2002; 94: 844-851.
- 15, , . Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003; 302: 643-646.
- 16, , , et al. Genetic epidemiology of BRCA mutations--family history detects less than 50% of the mutation carriers. Eur J Cancer. 2007; 43: 1713-1717.
- 17
- 18, , , et al. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res. 2000; 60: 1206-1210.
- 19, , , , . Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res. 2001; 7: 1739-1742.
- 20, , , . Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. Am J Surg Pathol. 2006; 30: 1357-1366.
- 21, , , et al. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol. 2006; 24: 707-715.
- 22, , , et al. Histopathological criteria and selection algorithms for BRCA1 genetic testing. Cancer Genet Cytogenet. 2009; 189: 105-111.
- 23, , , et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008; 26: 4282-4288.
- 24. BRCA1 functions as a breast stem cell regulator. J Med Genet. 2004; 41: 1-5.
- 25, , , et al. Individual and family characteristics associated with protein truncating BRCA1 and BRCA2 mutations in an Ontario population based series from the Cooperative Family Registry for Breast Cancer Studies. J Med Genet. 2003; 40: e91.
- 26, , , , . Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort. Clin Cancer Res. 2008; 14(: 4168-4174.
- 27, , , et al. Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat. 2002; 20: 65-73.Direct Link:
- 28, , , . Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998; 11: 155-168.
- 29, , , . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17: 1474-1481.
- 30, , , et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004; 17: 1545-1554.
- 31, , , et al. Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol. 2001; 115: 504-511.
- 32, , , et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol. 2002; 161: 1557-1565.
- 33, , , et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 5367-5374.
- 34, , , et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006; 19: 264-271.
- 35. Estimating the Dimension of a Model. The Annals of Statistics. 1978; 6: 461-464.
- 36. A Note on a General Definition of the Coefficient of Determination. Biometrika. 1991; 78: 691-692.
- 37, , , et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434: 913-917.
- 38, , , et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434: 917-921.
- 39, . Why are the majority of hereditary cases of early-onset breast cancer sporadic? A simulation study. Cancer Epidemiol Biomarkers Prev. 2000; 9: 805-812.
- 40, , , et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res. 1994; 54: 1645-1648.
- 41, , , et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res. 1993; 53: 5849-5852.
- 42, , , et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004; 203: 661-671.Direct Link:
- 43, , , . Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol. 2005; 18: 1321-1328.
- 44, , , et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001; 344: 539-548.
- 45, , , , , . Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc Natl Acad Sci U S A. 2005; 102: 9176-9181.
- 46, , , , . The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982; 31: 11-24.
- 47, , , et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest. 2002; 82: 737-746.
- 48, . Keratin expression in human tissues and neoplasms. Histopathology. 2002; 40: 403-439.Direct Link:
- 49, . Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif. 2003; 36 Suppl 1: 73-84.Direct Link:
- 50, , , et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A. 2008; 105: 1680-1685.
- 51, , , et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009; 15: 907-913.